dlt446 dlt446

dlt446 dlt446

Clinical Professor

Member of:

  • Neurology


Publication year:
All
61 - 70 out of 374Page size: 10
Sort by: Title
  1. Published

    Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

    Tepper, S., dlt446, dlt446, Reuter, U., Brandes, J. L., Doležil, D., Silberstein, S., Winner, P., Leonardi, D., Mikol, D. & Lenz, R., 2017, In: Lancet Neurology. 16, 6, p. 425-434

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial

    dlt446, dlt446, Lanteri-Minet, M., Pozo-Rosich, P., Ettrup, A., Christoffersen, C. L., Josiassen, M. K., Phul, R. & Sperling, B., 2022, In: The Lancet Neurology. 21, 7, p. 597-607 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

    Sun, H. Y., Dodick, D. W., Silberstein, S. D., Goadsby, P. J., Reuter, U., dlt446, dlt446, Saper, J. R., Cady, R., Chon, Y., Dietrich, J. & Lenz, R., Apr 2016, In: Lancet Neurology. 15, 4, p. 382-390 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

    Dodick, D. W., Goadsby, P. J., Silberstein, S. D., Lipton, R. B., Olesen, Jes, dlt446, dlt446, Wilks, K., Kudrow, D., Kroll, R., Kohrman, B., Bargar, R., Hirman, J., Smith, J. & ALD403 study investigators, A. S. I., Nov 2014, In: Lancet Neurology. 13, 11, p. 1100-1107 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    S100B and NSE in cluster headache -evidence for glial cell activation?

    Snoer, A., Vollesen, A. L. H., Beske, R. P., Guo, S., Hoffmann, J., Fahrenkrug, J., Joergesen, N. R., Martinussen, Torben, Jensen, Rigmor Højland & dlt446, dlt446, 2019, In: Cephalalgia. 39, 1, p. 51-52 2 p.

    Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

  6. Published

    S100B and NSE in Cluster Headache – Evidence for Glial Cell Activation?

    Snoer, A. H., Vollesen, A. L. H., Beske, R. P., Guo, S., Hoffmann, J., Jørgensen, Niklas Rye, Martinussen, Torben, dlt446, dlt446 & Jensen, Rigmor Højland, 2020, In: Headache. 60, 8, p. 1569-1580 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Risk Factors for the Development of Post-Traumatic Headache Attributed to Traumatic Brain Injury: A Systematic Review

    Andersen, A. M., Ashina, H., Iljazi, A., Al-Khazali, Haidar Muhsen Abdellah, Chaudhry, B., dlt446, dlt446, Ashina, Sait & Schytz, Henrik Winther, 2020, In: Headache. 60, 6, p. 1066-1075 10 p.

    Research output: Contribution to journal › Review › Research › peer-review

  8. Published

    Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

    Lipton, R. B., Tepper, S. J., Silberstein, S. D., Kudrow, D., dlt446, dlt446, Reuter, U., Dodick, D. W., Zhang, F., Rippon, G. A., Cheng, S. & Mikol, D. D., 2021, In: Cephalalgia. 41, 1, p. 6-16 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030

    Martelletti, P., Leonardi, M., Ashina, M., Burstein, R., Cho, S. J., Charway-Felli, A., Dodick, D. W., Gil-Gouveia, R., Grazzi, L., Lampl, C., MaassenVanDenBrink, A., Minen, M. T., Mitsikostas, D. D., Olesen, J., Owolabi, M. O., Reuter, U., Ruiz de la Torre, E., Sacco, S., Schwedt, T. J., Serafini, G. & 6 others, Surya, N., Tassorelli, C., Wang, S. J., Wang, Y., Wijeratne, T. & Raggi, A., 2023, In: Journal of Headache and Pain. 24, 1, 17 p., 140.

    Research output: Contribution to journal › Review › Research › peer-review

  10. Published

    Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial

    dlt446, dlt446, Lipton, R. B., Ailani, J., Versijpt, J., Sacco, S., Mitsikostas, D. D., Christoffersen, C. L., Sperling, B. & Ettrup, A., 2024, In: European Journal of Neurology. 31, 2, e16131.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...3 4 5 6 7 8 9 10 ...38 Next

ID: 920785